No Data
China National Accord Medicines' 2024 Profit Plunges 60%
Sinopharm is consistent: 2024 annual results report
It is proposed to set aside a goodwill impairment provision of nearly 0.9 billion yuan. China National Accord Medicines Corporation's revenue and net profit are expected to decline in 2024 | Quick Announcement.
① Due to the combined impact of intensified market competition and other factors, China National Accord Medicines Corporation expects a decline in both revenue and Net income for 2024. ② The company plans to make an impairment provision totaling 1.094 billion yuan for credit impairment losses and asset impairment losses.
China National Accord Medicines Corporation (000028.SZ) performance report: For the fiscal year 2024, net income attributable to the parent company is 0.642 billion yuan, a decrease of 59.83% year-on-year.
On March 17, Glonghui announced that China National Accord Medicines Corporation (000028.SZ) published its preliminary annual performance report for 2024. According to initial calculations, the company achieved revenue of 74.378 billion yuan for the year 2024, a year-on-year decrease of 1.46%; operating profit of 0.573 billion yuan, a year-on-year decrease of 76.76%; total profit of 0.575 billion yuan, a year-on-year decrease of 76.73%; net income attributable to shareholders of the listed company of 0.642 billion yuan, a year-on-year decrease of 59.83%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of 0.581 billion yuan, a year-on-year decrease of 62.08%; basic EPS of 1.
China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Biggest Owners Are Private Companies Who Got Richer After Stock Soared 3.4% Last Week
Improved Earnings Required Before China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Find Their Feet
Investors Aren't Buying China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Earnings